TORONTO, Nov. 30 /PRNewswire-FirstCall/ - ChondroGene Limited announced today that the Board of Directors approved the granting of 295,000 stock options to certain officers, employees and consultants. The options are exercisable at $0.70 per share for a period of 5 years from the date of grant. Stock options enhance the Company’s ability to attract and retain talented people by providing compensation incentives to employees, directors, officers and consultants for future services provided to ChondroGene.
About ChondroGene
-----------------
ChondroGene is focussed on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle, to detect and stage virtually any disease or medical condition from a simple blood sample. ChondroGene is currently applying the Sentinel Principle in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on ChondroGene, visit www.chondrogene.com.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release.
ChondroGene Limited
CONTACT: Dr. K. Wayne Marshall, President & CEO, (416) 650-0060 x234,wmarshall@chondrogene.com; Bruno Maruzzo, Corporate Development, (416)650-0060 x237, bmaruzzo@chondrogene.com